ARTCLINE appoints Peter Llewellyn-Davies as Chairman of the Supervisory Board and accelerates commercialization of innovative sepsis therapy

ARTCLINE appoints Peter Llewellyn-Davies as Chairman of the Supervisory Board and accelerates commercialization of innovative sepsis therapy

• ARTCLINE gains a prominent figure in the European biotech industry as Chairman of its Supervisory Board
• Broad market launch of ARTICE^® therapy for the treatment of immune dysfunction in septic shock scheduled for the second half of 2026

Rostock (Germany), 20 January 2026 – ARTCLINE, a biomedical company focused on the development of novel immune cell therapies for the treatment of septic shock, announces that Peter Llewellyn-Davies has joined its Supervisory Board, effective 1 January 2026 and has assumed the role of Chairman. With this appointment, the company is further advancing its commercialization strategy.

Peter Llewellyn-Davies is regarded as one of the leading personalities in the European biotechnology industry, with decades of international experience as a C-level executive, company founder, investor, and strategic advisor. As founder and CEO of Accellerate Partners, he supports management teams in growth strategies and scaling. He is also the founder and acting president of BIOTECH AUSTRIA, the Austrian biotech industry association. His career milestones include founding and managing invIOs and serving as CEO of APEIRON Biologics. Previously, he was CFO and CBO of Medigene AG and, as CFO of WILEX AG, was responsible for its IPO in 2006. Other senior positions include Executive Director of Finance, Controlling & Accounting at the Süd-Chemie Group. Peter Llewellyn-Davies is also a member of the supervisory board of Shield Therapeutics plc. The German-British citizen started his professional career at an investment bank in London.

Peter Llewellyn-Davies commented: “There is an enormous unmet medical need for septic shock therapies. Every day, more than 200 people die from this disease in Germany alone, and there are currently no adequate treatment options available. In my opinion, ARTCLINE's ARTICE^® therapy represents a highly innovative approach and holds the potential to deliver a genuine therapeutic breakthrough: by relieving and regenerating the immune system, mortality may be reduced, particularly in the second phase of immune dysfunction. I am delighted to provide strategic support to the company as it approaches market launch.”

The impairment of the immune system plays a decisive role in the course of sepsis. Even though modern intensive care treatments can address the initial phase of septic shock, many patients subsequently die due to immune dysfunction caused by secondary infections and/or organ failure. With its patented extracorporeal ARTICE^® therapy, which uses allogeneic donor immune cells to treat immune dysfunction in septic shock, ARTCLINE GmbH is addressing this unmet medical need for the first time. The donor immune cells are purified and clinically administered under a GMP manufacturing license.

The ARTICE^® therapy is currently being evaluated in the multicenter ReActIF-ICE study (NCT05442710). The last patient is expected to be enrolled in the first quarter of 2026, with detailed results to be published at the end of 2026. The aim of the study is to validate the clinical benefit of the therapy for treating immune dysfunction in septic shock. The broad market launch of the ARTICE^® procedure is already planned for the second half of 2026, as all components of the therapy have already received regulatory approval for general use in Germany.

Dr. Jens Altrichter, Managing Director and founder of ARTCLINE GmbH, said: “We would like to thank Peter for his support and confidence in our technology. We are very proud to have gained such an internationally experienced and well-connected Chairman to our Supervisory Board, whose strategic expertise and understanding of the life sciences industry and financial markets will help to strengthen ARTCLINE in a decisive phase of its development.”

Dirk Hessel, Managing Director of ARTCLINE GmbH, commented: “I am particularly looking forward to working with Peter in view of the upcoming market launch of our ARTICE^® therapy. I am convinced that this appointment will provide us with an excellent foundation to realize the potential of this innovative and urgently needed sepsis therapy.”

About ARTCLINE GmbH

ARTCLINE GmbH develops innovative therapeutic approaches for intensive care medicine. The company focuses on a novel, immune cell-based therapy for the treatment of septic shock – one of the major challenges for global health systems.

The ARTICE^® therapy, developed in collaboration between immunologists and dialysis specialists, uses allogeneic immune cells from healthy donors to temporarily support key functions of the patient's dysregulated immune system and help restore its activity.

For more information, please visit www.artcline.de or contact info@artcline.de. Follow ARTCLINE on LinkedIn.

Contact:       
ARTCLINE GmbH     
Dirk Hessel, Managing Director     
dirk.hessel@artcline.de     

Media inquiries:
MC Services AG
Eva Bauer / Julia von Hummel
Phone: +49-89-210228-0
artcline@mc-services.eu